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R818Advanced Cell Technologies, 
based in Worcester, 
Massachusetts, have developed a 
new procedure to create ‘ethical’ 
human embryonic stem cells, by 
removing single cells from early 
embryos in such a way that the 
remaining cells still remain viable. 
Considering the fact that the 
embryos in question are ‘leftovers’ 
from IVF that will be destroyed 
anyway, some observers have 
questioned the relevance of this 
work. However, in the long term, 
it may open the possibility of 
creating a line of matching stem 
cells for every baby born by IVF.
Meanwhile, another 
company, called Advanced Cell 
Therapeutics, has launched an 
effort to cash in on the hopes 
created by the developments in 
the stem cell field. It promises to 
cure a whole range of unrelated 
diseases, from Alzheimer’s 
through to multiple sclerosis, 
by injecting patients with stem 
cells from umbilical cord blood. 
After removal of red and white 
blood cells, the remaining 
population consists mainly of 
so-called CD34+ cells, from which 
white blood cells are eventually 
regenerated.
While the use of such cell 
preparations against specific 
blood disorders might still be 
plausible, experts are bewildered 
at the company’s claims that their 
stem cells can be used to treat 
afflictions of the nervous system, 
such as multiple sclerosis.
“This is not the natural choice of 
stem cell population to treat such 
disorders,” says Paul Fairchild 
from Oxford’s Sir William Dunn 
School of Pathology, “so the 
chance of observing any clinical 
benefit is minimal.”
The reassuring news is, 
however, that, other than a 
possible allergic reaction, the 
umbilical cord cells are not very 
likely to cause any damage 
either. Even though the white 
blood cells have been removed 
from the preparation, Fairchild 
Michael Gross looks at ethical 
issues raised by the business in 
stem cells.
Stem cell selling still expects that the cells will be rejected by the recipient’s immune 
system and eliminated within 
days. Thus, they will do no harm, 
and any long-term change in the 
patient’s condition is likely to be 
a manifestation of the placebo 
effect.
Thus far, the most contentious 
aspect of the whole enterprise 
is that it charges some of the 
most desperate and vulnerable 
members of society, those with 
incurable chronic illnesses, 
a substantial sum of money 
(newspapers reported a price 
of £12,000 for the injection) by offering a hope built on a 
treatment that has no foundation 
in science and has not been 
validated by any controlled clinical 
trial.
However, a recent investigation 
by the BBC’s Newsnight program 
revealed an even more worrying 
aspect. According to the program, 
the stem cell ‘cures’ which 
Advanced Cell Therapeutics 
sells via clinics in various 
countries, including Spain and 
the Netherlands, originate from 
a company called AllCells, which 
produced these cell populations 
purely for in vitro research Dilemmas: The potential in human stem cells is also throwing up new ethical issues. 
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Claims about the potential clinical 
benefit of human stem cells are 
not the only problem emerging 
from rapid developments in 
biology. The use of DNA analyses 
is proving a tempting target for 
many companies. There is no 
doubt that the sequencing of the 
human genome was a spectacular 
achievement, announced by 
President Clinton in 2000. But 
many commentators then glossed 
over the difficulties that lay ahead 
in transferring that information 
into useful medical advances.
So far, despite an explosion of 
research into how our genetic 
make-up puts us at risk of disease 
and affects our reaction to drugs 
or environmental toxins, there 
have been few concrete changes 
in the way doctors administer 
healthcare.
But companies looking to cash 
in by analysing DNA don’t have 
the same caution. Do your genes 
make you metabolise coffee 
and alcohol more quickly than 
most people? Are you prone to 
osteoporosis and Alzheimer’s 
in old age? Do you have the 
potential for sporting greatness? 
Plenty are willing to answer, if you 
are prepared to pay.
There’s just one problem: the 
genetic testing services available 
at present can’t give you that 
power — though they might aspire 
to, or insist they can.
Their fallibility was uncovered 
by a US Government 
Accountability Office investigation 
this summer. Over nearly a 
year, the GAO’s investigators 
anonymously approached four 
online companies for testing 
services. They posed as 14 
different would-be consumers 
with a variety of profiles such as 
age, weight, smoking and exercise 
habits. In reality, they sent 
samples of DNA provided from 
just two people — a 48-year-old 
man and a nine-month-old girl.
The GAO’s report shows that 
the companies, which charged 
between $89 and $395 for the 
tests, provided inconsistent 
results and offered vague and 
misleading advice to their 
supposed clients. One offered 
supposedly tailored nutritional 
supplements costing up to $1,200 
per year; they turned out to be 
run-of-the-mill multivitamin tablets 
that could be bought on the high 
street for $35 a year.
The companies to whom the 
samples were sent were: Suracell 
from Montclair, Sciona Inc. of 
Boulder, Colorado, Genaissance 
Pharmaceuticals of Newton, 
Massachusetts, and Genox and 
Genelex Corp. of Seattle — and 
all deny any impropriety.
The GAO said: “Although 
some types of diseases, such as 
cystic fibrosis, can be definitively 
diagnosed by looking at certain 
A US study of some companies 
offering DNA analysis has raised 
concerns. Nigel Williams reports.
Worries over 
consumer gene 
testspurposes. Representatives of that 
company pointed out that their 
cells are not guaranteed to be free 
from bacterial and viral infections 
to the standards that would be 
required for medical use.
The BBC program also alleges 
that Advanced Cell Therapeutics 
tried to obscure the origin of the 
cells by storing them in the UK, 
using the services of companies 
that were led to believe that these 
cells were for research purposes 
only. Following the revelations, 
however, this route is likely to be 
blocked, as the medical use of 
such cells would be illegal in the 
UK and even their handling and 
storage for other purposes than 
research might violate the Human 
Tissues Act drawn up in response 
to the organ retention scandals 
(Curr. Biol. 14, R254).
“It is important not to 
judge the potential future 
benefits of stem cell  
biology from the actions 
of those who have shown 
such flagrant disregard for 
the lives of their patients.”
In a global market, however, 
people will continue to find ways 
of offering dubious medicine, 
using internet marketing and 
legal loopholes in countries 
around the world. Advanced Cell 
Therapeutics, for example, has 
been carrying out its treatments 
in Ireland until recently, and, when 
the authorities stepped in, there 
were press reports suggesting 
that the company offered the 
treatment on board a ferry, in 
international waters instead. 
Similarly, the company Medra, 
based in Malibu, California, offers 
injections of “human fetal stem 
cells” to treat diseases ranging 
from Alzheimer’s through to 
ulcerative colitis, to be carried 
out in the Dominican Republic. 
The company’s fact sheet guards 
tactful silence on the origin of 
these cells.
Fairchild concludes: “While 
the practice of companies such 
as Advanced Cell Therapeutics 
and Medra is truly shocking, it is important not to judge the 
potential future benefits of stem 
cell biology from the actions of 
those who have shown such 
flagrant disregard for the lives of 
their patients.”
So, is there any real hope for 
patients with chronic disease to 
benefit from stem cell therapies 
in the near future? Most 
treatment options that are being 
investigated in the lab right now 
will need many years before 
they might reach the patient. 
However, there is some more promising, if cautious, news on 
stem cells. The company Geron, 
based at Menlo Park, California, 
is testing a range of stem 
cell treatments in preclinical 
trials, and is expecting to 
start the first Phase I clinical 
trial early next year, which will 
most likely involve a possible 
treatment for acute spinal cord 
injury. 
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